|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||48.33 - 48.80|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||17.44|
|Forward dividend & yield||1.75 (3.60%)|
|Ex-dividend date||26 May 2022|
|1y target est||N/A|
(Bloomberg) -- As earnings season gathers pace, a slew of weak results and a hawkish European Central Bank risk spoiling the rally that spurred European equities to their best-ever start to a year. Most Read from BloombergAdani Tries to Calm Investors With 413-Page Hindenburg RebuttalAdani Rout Hits $68 Billion as Fight With Hindenburg IntensifiesRussia Can’t Replace the Energy Market Putin BrokeHistoric Crash for Memory Chips Threatens to Wipe Out EarningsThis week, it’s the turn of banks and p
Sanofi (NASDAQ: SNY) and AstraZeneca's (NASDAQ: AZN) application for the respiratory syncytial virus (RSV) vaccine candidate called nirsevimab was recently accepted for review by the U.S. Food and Drug Administration (FDA) as a protective option for all infants. Nirsevimab is known by the trade name Beyfortus in the European Union and the United Kingdom, and the FDA expects to make an approval decision on the RSV vaccine in the third quarter of this year.
In the latest trading session, Sanofi (SNY) closed at $48.49, marking a -0.66% move from the previous day.